Tacalyx extends seed round to over €14 million
New investor Thuja Capital leads the extension; Evan Castiglia joins the Board of Directors.
Tacalyx has extended its seed financing to over €14 million. The extension was led by new investor Thuja Capital, and Evan Castiglia, Partner at Thuja Capital, joins the Board of Directors. Thuja joins the existing investors Boehringer Ingelheim Venture Fund, Kurma Partners, High-Tech Gründerfonds, coparion, Idinvest/Eurazeo, Creathor Ventures and the Max Planck Society.
With its platform, Tacalyx has built a pipeline of seven projects against known and novel TACAs. The new funds take two antibodies to the late preclinical stage and advance several earlier programmes. Academic collaborations support the discovery of new TACAs.
"With these added funds, we will be able to make significant progress on two of our assets to clinical candidate stage, and advance others so they are ready for preclinical development."
— Dr. Peter Sondermann, then CEO and co-founder
"We see great potential with the expertise and technology of Tacalyx in the emerging field of glycan biology and believe this technology platform can create novel treatment options for patients with excellent specificity across multiple solid tumor indications."
— Evan Castiglia, Partner, Thuja Capital
